Alice S. Bexon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alice S. Bexon has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Erol Wiegert
Bexon Clinical Consulting (United States) 10 Montclair
31 shared publications - Jaime Rafael Merchan
Miller School of Medicine, University of Miami, Miami, FL 33136, USA
31 shared publications - Jen Boughton
Vyriad 6
31 shared publications - Kah-Whye Peng
Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
31 shared publications - Luke Russell
Vyriad 6
31 shared publications - Manish Ramesh Patel
University of Minnesota 3 Minneapolis, MN
31 shared publications
Latest Publications
- Open Access
- 11 August 2026
- Published by American Association for Cancer Research (AACR)
Table S11 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors
Study population representativeness
- 11 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S11 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors
Study population representativeness
- Open Access
- 11 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors
Trial schema for parts 1–3. *Expansion cohort into patients with neuroendocrine tumors (NET). Based on the lack of efficacy in the combination arm, further monotherapy expansion cohorts were abandoned. † Labeled dose/regimen of avelumab. ‡ Combination therapy safety lead in. No attrition was observed.
- 11 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors
Trial schema for parts 1–3. *Expansion cohort into patients with neuroendocrine tumors (NET). Based on the lack of efficacy in the combination arm, further monotherapy expansion cohorts were abandoned. † Labeled dose/regimen of avelumab. ‡ Combination therapy safety lead in. No attrition was observed.
- Open Access
- 11 August 2026
- Published by American Association for Cancer Research (AACR)
Table S10 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors
Part 1 disease response and SPECT/CT positivity
- 11 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors
Part 1 disease response and SPECT/CT positivity
- Open Access
- 11 August 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors
Injection volume, site size and image guidance criteria
- 11 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors
Injection volume, site size and image guidance criteria
- Open Access
- 11 August 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors
IRRs and CRS related to intravenous VV1 monotherapy (part 2).
- 11 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors
IRRs and CRS related to intravenous VV1 monotherapy (part 2).
- Open Access
- 11 August 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors
DLT definition VV1 combination therapy
- 11 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors
DLT definition VV1 combination therapy
- Open Access
- 11 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors
Serum IFNß and cytokine levels following VV1 monotherapy and in combination with avelumab. A, Mean serum IFNß following IT administration of VV1 monotherapy dose escalation (part 1). Each DL has 3–6 patients. B, Serum IFNβ following 30–90-minute IV infusions of high-dose VV1 (1 × 1011 TCID50) monotherapy (part 2). Each line represents a unique patient (n = 6). C, Mean [95% confidence interval (CI)] serum IFNβ following IV infusions of VV1 (1.7 × 1010 TCID50) monotherapy (part 2). Each dot represents a unique patient (n = 23). Limit of detection for IFNβ was 1.2 pg/mL. D, Mean (95% CI) serum IFNβ over time following 30-minute IV infusions of VV1 (1.7 × 1010 TCID50) + labeled dose/regimen of avelumab (part 3). Each dot represents a unique patient (n = 16). Limit of detection for IFNβ was 1.2 pg/mL. E, Mean (±SEM) cytokine levels following 30-minute IV infusion of VV1 (1.7 × 1010 TCID50) monotherapy (part 2; n = 7). F, Mean (±SEM) cytokine levels following 30-minute IV infusion of high dose VV1 (1 × 1011 TCID50) monotherapy (part 2; n = 6).
- 11 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors
Serum IFNß and cytokine levels following VV1 monotherapy and in combination with avelumab. A, Mean serum IFNß following IT administration of VV1 monotherapy dose escalation (part 1). Each DL has 3–6 patients. B, Serum IFNβ following 30–90-minute IV infusions of high-dose VV1 (1 × 1011 TCID50) monotherapy (part 2). Each line represents a unique patient (n = 6). C, Mean [95% confidence interval (CI)] serum IFNβ following IV infusions of VV1 (1.7 × 1010 TCID50) monotherapy (part 2). Each dot represents a unique patient (n = 23). Limit of detection for IFNβ was 1.2 pg/mL. D, Mean (95% CI) serum IFNβ over time following 30-minute IV infusions of VV1 (1.7 × 1010 TCID50) + labeled dose/regimen of avelumab (part 3). Each dot represents a unique patient (n = 16). Limit of detection for IFNβ was 1.2 pg/mL. E, Mean (±SEM) cytokine levels following 30-minute IV infusion of VV1 (1.7 × 1010 TCID50) monotherapy (part 2; n = 7). F, Mean (±SEM) cytokine levels following 30-minute IV infusion of high dose VV1 (1 × 1011 TCID50) monotherapy (part 2; n = 6).
- Open Access
- 11 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors
TRAEs and viremia following VV1 monotherapy and in combination with avelumab. A, All TRAEs observed in ≥15% of patients by grade, plus all treatment-related grade 3 and 4 events. *After part 1, CRS type symptoms were documented with checkbox in the CRF. B, Viremia following 30–90-minute intravenous (IV) infusions of high-dose VV1 (1 × 1011 TCID50) monotherapy (part 2). Each line represents a unique patient (n = 4). C, Viremia following 15–180-minute IV infusions of VV1 (1.7 × 1010 TCID50) monotherapy (part 2). D, Viremia following 30-minute IV infusions of VV1 (1.7 × 1010 TCID50) + labeled dose/regimen of avelumab (part 3). ALT, alanine aminotransferase; COPD, chronic obstructive pulmonary disease; TRAE, treatment-related AE.
- 11 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors
TRAEs and viremia following VV1 monotherapy and in combination with avelumab. A, All TRAEs observed in ≥15% of patients by grade, plus all treatment-related grade 3 and 4 events. *After part 1, CRS type symptoms were documented with checkbox in the CRF. B, Viremia following 30–90-minute intravenous (IV) infusions of high-dose VV1 (1 × 1011 TCID50) monotherapy (part 2). Each line represents a unique patient (n = 4). C, Viremia following 15–180-minute IV infusions of VV1 (1.7 × 1010 TCID50) monotherapy (part 2). D, Viremia following 30-minute IV infusions of VV1 (1.7 × 1010 TCID50) + labeled dose/regimen of avelumab (part 3). ALT, alanine aminotransferase; COPD, chronic obstructive pulmonary disease; TRAE, treatment-related AE.